Immune privilege and HIV-1 persistence in the CNS

Yuri Persidsky, Larisa Poluektova

Research output: Contribution to journalReview article

49 Citations (Scopus)

Abstract

Human immunodeficiency virus-1 (HIV-1) neuroinvasion occurs early (during period of initial viremia), leading to infection of a limited amount of susceptible cells with low CD4 expression. Protective cellular and humoral immunity eliminate and suppress viral replication relatively quickly due to peripheral immune responses and the low level of initial central nervous system (CNS) infection. Upregulation of the brain protective mechanisms against lymphocyte entry and survival (related to immune privilege) helps reduce viral load in the brain. The local immune compartment dictates local viral evolution as well as selection of cytotoxic lymphocytes and immunoglobulin G specificity. Such status can be sustained until peripheral immune anti-viral responses fail. Activation of microglia and astrocytes, due to local or peripheral triggers, increases chemokine production, enhances traffic of infected cells into the CNS, upregulates viral replication in resident brain macrophages, and significantly augments the spread of viral species. The combination of these factors leads to the development of HIV-1 encephalitis-associated neurocognitive decline and patient death. Understanding the immune-privileged state created by virus, the brain microenvironment, and the ability to enhance anti-viral immunity offer new therapeutic strategies for treatment of HIV-1 CNS infection.

Original languageEnglish (US)
Pages (from-to)180-194
Number of pages15
JournalImmunological Reviews
Volume213
Issue number1
DOIs
StatePublished - Oct 1 2006

Fingerprint

HIV-1
Central Nervous System
Central Nervous System Infections
Brain
Up-Regulation
Lymphocytes
Viremia
Microglia
Encephalitis
Humoral Immunity
Viral Load
Chemokines
Cellular Immunity
Astrocytes
Immunity
Immunoglobulin G
Macrophages
Viruses
Survival
Therapeutics

Keywords

  • Blood-brain barrier
  • HIV-1 encephalitis
  • Immune privilege
  • Indoleamine 2,3-dioxygenase
  • Monocytes/macrophages

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Immune privilege and HIV-1 persistence in the CNS. / Persidsky, Yuri; Poluektova, Larisa.

In: Immunological Reviews, Vol. 213, No. 1, 01.10.2006, p. 180-194.

Research output: Contribution to journalReview article

Persidsky, Yuri ; Poluektova, Larisa. / Immune privilege and HIV-1 persistence in the CNS. In: Immunological Reviews. 2006 ; Vol. 213, No. 1. pp. 180-194.
@article{ba9d3d824d90496a833277faaa43ce97,
title = "Immune privilege and HIV-1 persistence in the CNS",
abstract = "Human immunodeficiency virus-1 (HIV-1) neuroinvasion occurs early (during period of initial viremia), leading to infection of a limited amount of susceptible cells with low CD4 expression. Protective cellular and humoral immunity eliminate and suppress viral replication relatively quickly due to peripheral immune responses and the low level of initial central nervous system (CNS) infection. Upregulation of the brain protective mechanisms against lymphocyte entry and survival (related to immune privilege) helps reduce viral load in the brain. The local immune compartment dictates local viral evolution as well as selection of cytotoxic lymphocytes and immunoglobulin G specificity. Such status can be sustained until peripheral immune anti-viral responses fail. Activation of microglia and astrocytes, due to local or peripheral triggers, increases chemokine production, enhances traffic of infected cells into the CNS, upregulates viral replication in resident brain macrophages, and significantly augments the spread of viral species. The combination of these factors leads to the development of HIV-1 encephalitis-associated neurocognitive decline and patient death. Understanding the immune-privileged state created by virus, the brain microenvironment, and the ability to enhance anti-viral immunity offer new therapeutic strategies for treatment of HIV-1 CNS infection.",
keywords = "Blood-brain barrier, HIV-1 encephalitis, Immune privilege, Indoleamine 2,3-dioxygenase, Monocytes/macrophages",
author = "Yuri Persidsky and Larisa Poluektova",
year = "2006",
month = "10",
day = "1",
doi = "10.1111/j.1600-065X.2006.00440.x",
language = "English (US)",
volume = "213",
pages = "180--194",
journal = "Immunological Reviews",
issn = "0105-2896",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Immune privilege and HIV-1 persistence in the CNS

AU - Persidsky, Yuri

AU - Poluektova, Larisa

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Human immunodeficiency virus-1 (HIV-1) neuroinvasion occurs early (during period of initial viremia), leading to infection of a limited amount of susceptible cells with low CD4 expression. Protective cellular and humoral immunity eliminate and suppress viral replication relatively quickly due to peripheral immune responses and the low level of initial central nervous system (CNS) infection. Upregulation of the brain protective mechanisms against lymphocyte entry and survival (related to immune privilege) helps reduce viral load in the brain. The local immune compartment dictates local viral evolution as well as selection of cytotoxic lymphocytes and immunoglobulin G specificity. Such status can be sustained until peripheral immune anti-viral responses fail. Activation of microglia and astrocytes, due to local or peripheral triggers, increases chemokine production, enhances traffic of infected cells into the CNS, upregulates viral replication in resident brain macrophages, and significantly augments the spread of viral species. The combination of these factors leads to the development of HIV-1 encephalitis-associated neurocognitive decline and patient death. Understanding the immune-privileged state created by virus, the brain microenvironment, and the ability to enhance anti-viral immunity offer new therapeutic strategies for treatment of HIV-1 CNS infection.

AB - Human immunodeficiency virus-1 (HIV-1) neuroinvasion occurs early (during period of initial viremia), leading to infection of a limited amount of susceptible cells with low CD4 expression. Protective cellular and humoral immunity eliminate and suppress viral replication relatively quickly due to peripheral immune responses and the low level of initial central nervous system (CNS) infection. Upregulation of the brain protective mechanisms against lymphocyte entry and survival (related to immune privilege) helps reduce viral load in the brain. The local immune compartment dictates local viral evolution as well as selection of cytotoxic lymphocytes and immunoglobulin G specificity. Such status can be sustained until peripheral immune anti-viral responses fail. Activation of microglia and astrocytes, due to local or peripheral triggers, increases chemokine production, enhances traffic of infected cells into the CNS, upregulates viral replication in resident brain macrophages, and significantly augments the spread of viral species. The combination of these factors leads to the development of HIV-1 encephalitis-associated neurocognitive decline and patient death. Understanding the immune-privileged state created by virus, the brain microenvironment, and the ability to enhance anti-viral immunity offer new therapeutic strategies for treatment of HIV-1 CNS infection.

KW - Blood-brain barrier

KW - HIV-1 encephalitis

KW - Immune privilege

KW - Indoleamine 2,3-dioxygenase

KW - Monocytes/macrophages

UR - http://www.scopus.com/inward/record.url?scp=33748750058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748750058&partnerID=8YFLogxK

U2 - 10.1111/j.1600-065X.2006.00440.x

DO - 10.1111/j.1600-065X.2006.00440.x

M3 - Review article

C2 - 16972904

AN - SCOPUS:33748750058

VL - 213

SP - 180

EP - 194

JO - Immunological Reviews

JF - Immunological Reviews

SN - 0105-2896

IS - 1

ER -